Inhibrx EBITDA Margin 2020-2022 | INBX
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Inhibrx (INBX) over the last 10 years. The current EBITDA margin for Inhibrx as of March 31, 2022 is .
| Inhibrx EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2022-03-31 |
$0.01B |
$-0.08B |
-1050.00% |
| 2021-12-31 |
$0.01B |
$-0.07B |
-925.00% |
| 2021-09-30 |
$0.01B |
$-0.07B |
-900.00% |
| 2021-06-30 |
$0.01B |
$-0.07B |
-590.91% |
| 2021-03-31 |
$0.01B |
$-0.06B |
-453.85% |
| 2020-12-31 |
$0.01B |
$-0.06B |
-438.46% |
| 2020-06-30 |
$0.01B |
$-0.04B |
-840.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.452B |
$0.007B |
|
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
|
